PS3-2 TROPiCS-02 3期研究的最终OS分析：针对HR+/HER2-转移性乳腺癌的sacituzumab govitecan研究

IF 56.7 1区医学 Q1 ONCOLOGY

Annals of Oncology Pub Date : 2024-10-01 DOI:10.1016/j.annonc.2024.07.716

H.S. Rugo , A. Bardia , F. Marme , J. Cortes , P. Schmid , D. Loirat , O. Tredan , E. Ciruelos , F. Dalenc , P. Gomez Pardo , K.L. Jhaveri , R. Delaney , T. Valdez , O. Yoon , H. Wang , W. Verret , S.M. Tolaney

引用次数: 0

摘要

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

PS3-2 Final OS analysis from the phase 3 TROPiCS-02 study: sacituzumab govitecan in HR+/HER2− metastatic breast cancer

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annals of Oncology 医学-肿瘤学

CiteScore

63.90

自引率

1.00%

发文量

3712

审稿时长

2-3 weeks

期刊介绍： Annals of Oncology, the official journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, offers rapid and efficient peer-reviewed publications on innovative cancer treatments and translational research in oncology and precision medicine. The journal primarily focuses on areas such as systemic anticancer therapy, with a specific emphasis on molecular targeted agents and new immune therapies. We also welcome randomized trials, including negative results, as well as top-level guidelines. Additionally, we encourage submissions in emerging fields that are crucial to personalized medicine, such as molecular pathology, bioinformatics, modern statistics, and biotechnologies. Manuscripts related to radiotherapy, surgery, and pediatrics will be considered if they demonstrate a clear interaction with any of the aforementioned fields or if they present groundbreaking findings. Our international editorial board comprises renowned experts who are leaders in their respective fields. Through Annals of Oncology, we strive to provide the most effective communication on the dynamic and ever-evolving global oncology landscape.